

# Selective drug delivery to bone using acidic oligopeptides

著者	Ishizaki Junko, Waki Yoshihiro, Takahashi-Nishioka Tatsuo, Yokogawa Koichi, Miyamoto Kenichi
journal or publication title	Journal of Bone and Mineral Metabolism
volume	27
number	1
page range	1-8
year	2009-01-01
URL	<a href="http://hdl.handle.net/2297/12348">http://hdl.handle.net/2297/12348</a>

doi: 10.1007/s00774-008-0004-z

## Review

### Selective drug targeting to bone using acidic oligopeptides

Junko Ishizaki<sup>a</sup>, Yoshihiro Waki<sup>b</sup>, Tatsuo Takahashi-Nishioka<sup>c</sup>, Koichi Yokogawa<sup>d</sup>, Ken-ichi Miyamoto<sup>d,\*</sup>

<sup>a</sup>Department of Clinical Drug Informatics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa 920-1192, Japan

<sup>b</sup>Department of Pharmacology, Nihon Pharmaceutical University, Saitama 362-0806, Japan

<sup>c</sup>Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa 920-1181, Japan

<sup>d</sup>Department of Hospital Pharmacy and Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8641, Japan

\* Corresponding author: Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan.  
Tel: +81-76-265-2045; Fax: +81-76-234-4280;

E-mail addresses: [junishi@kenroku.kanazawa-u.ac.jp](mailto:junishi@kenroku.kanazawa-u.ac.jp) (J. Ishizaki), [waki@nichiyaku.ac.jp](mailto:waki@nichiyaku.ac.jp) (Y.

Waki), [t-takahashi@hokuriku-u.ac.jp](mailto:t-takahashi@hokuriku-u.ac.jp) (T. Takahashi), [yokogawa@kenroku.kanazawa-u.ac.jp](mailto:yokogawa@kenroku.kanazawa-u.ac.jp) (K.

Yokogawa), [miyaken@kenroku.kanazawa-u.ac.jp](mailto:miyaken@kenroku.kanazawa-u.ac.jp) (K. Miyamoto)

**Key words:** drug delivery, acidic oligopeptide, estradiol, levofloxacin, tissue-non-specific alkaline phosphatase.

## **Introduction**

Bone is susceptible to a range of diseases, like other tissues. However, it is generally difficult to deliver and retain drugs in the bone. Bone is composed unique materials such as the inorganic compound hydroxyapatite (HAP) and bone-matrix proteins, which are quite different from the components of other tissues. Among them, HAP may be a promising target for selective drug delivery to bone.

Now, two promising methods have been reported for selective drug delivery to the bone as a target HAP. One is a class of molecules known as bisphosphonates. Systemic administration of bisphosphonates commonly results in 20-50% deposition of the molecule at bone tissues, with minimal accumulation at other sites [1]. These compounds not only show anti-osteoporosis effect by themselves [2] but are useful as the drug delivery carrier to the bone [3-6]. Another is the oligopeptide having high affinity to the bone, described in this review.

The structures of several bone non-collagenous proteins that bind to HAP have a repeating sequence of acidic amino acids (Asp, Glu), which may serve as a HAP binding site. Osteopontin and bone sialoprotein, two major non-collagenous proteins in bone, have L-Asp and L-Glu repetitive sequences, respectively (Fig. 1), and rapidly bind to HAP after they are secreted in osteoblastic cell culture [7-9]. Thus, these acidic oligopeptides are candidate bone-targeting carriers. It was hypothesized that, after systemic administration, a drug tagged with such an oligopeptide would be selectively delivered and bind to bone, where the active drug would be released gradually during bone remodeling processes.

This review describes the properties of acidic oligopeptides and introduces the tagging of three model drugs, estradiol, quinolone antibiotics, and tissue-nonspecific alkaline phosphatase (TNSALP), with an acidic oligopeptide to examine the clinical feasibility of the acidic oligopeptide strategy for selective drug delivery to bone.

### **Bioproperties of acidic oligopeptides**

Homo-oligopeptides consisting of two to ten acidic amino acid residues, conjugated with 9-fluorenylmethylchloroformate (Fmoc) or fluorescein (FITC), were synthesized by routine solid-phase methods (Fig. 2). The dissociation constant ( $K_d$ ) decreased with increasing numbers of acidic amino acid residues, and the binding rate ( $B_{max}$ ) reached almost maximum at a length of six residues. The affinity for HAP was not related to the optical isomeric form (L or D) or the acidic amino acid species (Asp or Glu) [10]. When intravenously administered, fluorescein-labeled L-Asp hexapeptide (FITC-D<sub>6</sub>) disappeared from the plasma with a biological half-life of 60 min, and 95% of the administered FITC was excreted within 24 h, but FITC-D<sub>6</sub> rapidly bound and retained on the bone and teeth (Fig. 3) and was detectable in bone tissues even at 14 d after administration, but it was undetectable in other tissues [11]. Among the isomeric forms of the amino acids, the retention time was much longer for D-amino acid oligopeptides than for L-peptides. However, the L-amino acid (Asp) hexapeptide was chosen, because the D-peptide may be insensitive to hydrolysis in bone thus would not release the tagged drug.

## Oligopeptide-tagged estradiol for osteoporosis

Osteoporosis is a serious problem for postmenopausal and aged women, and estrogen deficiency plays a causative role in its development. Estrogen can act directly or indirectly on osteoblasts and osteoclasts through estrogen receptor-mediated mechanisms [12-16], resulting in an anabolic effect on bone formation in estrogen-deficient animal models [17, 18]. Estrogen replacement therapy is an effective treatment in postmenopausal women to prevent reduction of bone mineral density [19]. However, systemically administered estrogen is widely distributed to tissues other than bone, and prolonged therapy may increase the risks of endometritis, breast and endometrial cancer, and intrauterine hemorrhage [20, 21]. The development of osteoporosis therapies that are more efficient and selective for bone is desirable to avoid such adverse reactions.

Estradiol ( $E_2$ ) was tagged with the L-Asp hexapeptide at the 3-position ( $E_2$ -3D<sub>6</sub>) or the 17 $\beta$ -position ( $E_2$ -17 $\beta$ D<sub>6</sub>) via a succinate ester (Fig. 4), and the pharmacokinetics and anti-osteoporotic effects of these compounds were examined [10, 22]. First, the binding affinities of these compounds at human estrogen receptors, ER $\alpha$  and ER $\beta$ , were tested *in vitro*. The affinities of  $E_2$ -3D<sub>6</sub> and  $E_2$ -17 $\beta$ D<sub>6</sub> to both estrogen receptors were about 100-fold and 10,000-fold, respectively, less than those of estradiol. Moreover, it is unlikely that the tagged estradiols can permeate through the plasma membrane, because of their hydrophilicity and large molecular size, and it seems probable that hydrolysis of the ester bond between estradiol and the L-Asp hexapeptide portion would be required for the tagged estradiols to show biological activity. At 6 h after a single intravenous administration (3.7  $\mu$ mol/kg), the apparent tissue-to-plasma

concentration ratio of the tagged estradiols was almost 1.0 in most tissues and organs, indicating that these compound could not distribute or accumulate in tissues. Among the tissues examined, untagged estradiol was most highly distributed in the uterus, where it might cause adverse effects such as endometritis, whereas the accumulation of the tagged estradiols in the uterus was clearly lower. On the other hand, tagged estradiol was distributed to bone at 50-fold the level of untagged estradiol. Moreover, the level of tagged estradiol in bone decreased very slowly, falling to basal level ( $10.5 \pm 3.3$  pmol/g) by 7 days, whereas untagged estradiol declined to the basal range within 1 day after injection.

It is well known that estradiol with a mono- or di-ester at position 3 or/and 17 shows prolonged estrogenic effects in the body due to the biological stability of esterified estradiol [23, 24]. This is so because removal of the ester is necessary for further metabolism and excretion of estradiol, and the de-esterification step appears to be the rate-limiting process in the elimination [25]. Indeed, at 6 h after the injection of untagged estradiol, the plasma concentration of estradiol had decreased almost to the basal level ( $7.6 \pm 1.9$  pmol/mL), whereas the tagged estradiols remained in the circulation at 6 h ( $E_2-3D_6$ ;  $26.7 \pm 9.0$  pmol/mL,  $E_2-17\beta D_6$ ;  $22.0 \pm 12.0$  pmol/mL, respectively). The lower total body clearance ( $CL_{tot}$ ) of the tagged estradiols, compared with that of untagged estradiol, may result from superior biological stability. This would be favorable for the long-term action of tagged estradiol in bone.

When tagged estradiol (0.11, 0.37, or 1.1  $\mu$ mol/kg, every seventh day) or untagged estradiol (0.37  $\mu$ mol/kg, every third day) was intravenously administered into ovariectomized

(OVX) mice for 28 days, the tagged estradiol dose-dependently reversed the decreased bone mineral density (BMD), and the estrogenic effects were selective to bone. The untagged estradiol increased not only the BMD but also the weights of the uterus and liver [10, 22]. Estradiol caused hypertrophy of uterine tissues and fatty degeneration in the liver. These results indicate that tagged estradiol reduced the risk of systemic adverse effects of estradiol, while retaining the osteogenic effect in bone.

The retention of E<sub>2</sub>-3D<sub>6</sub> in the blood circulation and bone and its anti-osteoporotic effects were greater than those of E<sub>2</sub>-17βD<sub>6</sub> [10,22]. The difference may be attributable to the greater stability of E<sub>2</sub>-3D<sub>6</sub> to hydrolysis, compared with E<sub>2</sub>-17βD<sub>6</sub>, so that the retention in bone is longer for E<sub>2</sub>-3D<sub>6</sub> than for E<sub>2</sub>-17βD<sub>6</sub>. It is likely that the tagged estradiols bound to bone are gradually hydrolyzed on the bone surface, possibly by peptidases, acid secreted by osteoclasts, and/or non-specific esterases, and that the released estradiol then acts via estrogen receptors.

Thus, these acidic oligopeptide-tagged estradiols, E<sub>2</sub>-3D<sub>6</sub> and E<sub>2</sub>-17βD<sub>6</sub>, are promising candidates for the treatment of postmenopausal osteoporosis. The prolonged effect and selective delivery to bone should extend the medication interval and reduce the adverse effects of estradiol. However, when considering the clinical use of these oligopeptide-tagged estradiols, intravenous injection is undesirable because of the potential for poor compliance. The bioavailability of E<sub>2</sub>-17βD<sub>6</sub> after oral administration was less than 10%. Therefore, Yokogawa et al. have developed an intranasal preparation to increase the bioavailability of the tagged molecules [26]. The bioavailability of E<sub>2</sub>-17βD<sub>6</sub> after intranasal administration was increased to 75% by incorporating

2,6-di-*O*-methyl- $\beta$ -cyclodextrin into the formulation, thereby creating an inclusion complex with E<sub>2</sub>-17 $\beta$ D<sub>6</sub> that could achieve prolonged residence in the nasal cavity. The acidic oligopeptide-tagged estrogen provided increased medication compliance because of its long-acting and easy administration, and it increased anti-osteoporotic efficacy because of selective delivery to bone and reduced adverse effects of estradiol, resulting in improved quality of life for patients.

### **Oligopeptide-tagged quinolone antibiotics for osteomyelitis**

Osteomyelitis is a progressive infectious process resulting in inflammatory destruction of bone, bone necrosis, and new bone formation. Chronic osteomyelitis is generally treated with surgical debridement, following the administration of parenteral antibiotics such as  $\beta$ -lactams or aminoglycosides. Without adequate debridement, most antibiotic regimens fail, regardless of the duration of therapy. Even when all necrotic tissue has been removed, the remaining bed of tissue must be considered as contaminated with the responsible pathogens. Thus, it is recommended to treat the patient with antibiotics for at least 4 weeks [27-29]. Moreover, the serum bactericidal titer, which is defined as the maximal dilution of the patient's serum that is able to kill the infecting organism *in vitro*, should be 1:4 or greater for a cure [30]. Thus, high doses and long-term administration of antibiotics are required for the treatment of osteomyelitis, because the delivery of antibiotics to bone is difficult. As the fluoroquinolones have a broad spectrum of activity *in vitro*, including activity against Gram-negative organisms, *Staphylococcus aureus*, and *S. epidermidis*

[31], improving their bone distribution should increase their therapeutic effectiveness.

Takahashi et al. have designed levofloxacin (LVFX) tagged with the L-Asp hexapeptide at position 3 in the pyridone carbonic acid moiety, an active center of the drug, via a glycolate ester, (LVFX-3D<sub>6</sub>) and norfloxacin (NFLX) tagged with the L-Asp hexapeptide at position N7 in the piperazinyl group via a glycolate and succinate linker (NFLX-7D<sub>6</sub>)(Fig. 5) [32]. The minimum inhibitory concentrations (MIC) for anti-microbial activity of LVFX-3D<sub>6</sub> and NFLX-7D<sub>6</sub> against *S. aureus in vitro* were 100- and 60-fold less, respectively, than those of the respective untagged drugs. One reason for this may be the increased hydrophilicity, arising from the acidic oligopeptide tag. Fluoroquinolones act by inhibiting bacterial topoisomerase II, which is responsible for the replication of double-stranded DNA, and thus must cross the bacterial membrane to be effective [33, 34]. The marked reduction of the antimicrobial activity of tagged quinolones indicates that the release of the parent drug by hydrolysis was required for biological activity, as in the case of tagged estrogen.

The pharmacokinetic parameters of LVFX-3D<sub>6</sub> and NFLX-7D<sub>6</sub> after a single intravenous injection are shown in Table 1. The AUC value of each tagged drug was two-fold that of the respective parent drug. In contrast, the Vdss value was significantly less for the tagged drugs than for the parent drugs, indicating a low distribution of the tagged compounds into tissues. The biological half-life was not changed by conjugation. Although these fluoroquinolones themselves have some affinity for calcium or bone, the level of tagged drugs in bone was more than 100-fold that of the parent drugs for at least 7 days after injection. After injection of LVFX-3D<sub>6</sub>, the

resulting LVFX was detected in bone marrow at about 1% of the concentration of LVFX-3D<sub>6</sub> in bone and was continuously released for 7 days. It is known that fluoroquinolones show extensive tissue penetration, and as a result, can cause adverse effects in various tissues, including the cardiovascular system, central nervous system, skin, liver, musculoskeletal system, and kidneys [35, 36]. The risk of adverse events may be decreased by conjugation with an oligopeptide because of lower distribution into tissues due to the increased hydrophilicity.

The therapeutic effect of tagged drugs on osteomyelitis was evaluated using a murine model of osteomyelitis, which was prepared by inoculation of *S. aureus* into the tibia. The amount of *S. aureus* remaining in the tibia after a single intravenous injection of the drug (27.7 mmol/kg for LVFX and LVFX-3D<sub>6</sub>; 31.3 mmol/kg for NFLX and NFLX-7D<sub>6</sub>) was determined, but only a slight reduction in the number of *S. aureus* was observed after the administration of LVFX, and no effect was seen for NFLX and NFLX-7D<sub>6</sub>. The anti-microbial effect of LVFX was temporary, and the number of *S. aureus* had recovered to the level of the untreated control group at 6 days after administration. On the other hand, LVFX-3D<sub>6</sub> suppressed the growth of *S. aureus* for at least 6 days, showing a prolonged effect. Nevertheless, the effect of LVFX-3D<sub>6</sub> was not sufficient to kill *S. aureus*, presumably because the LVFX concentration generated from LVFX-3D<sub>6</sub> in the bone was insufficient to kill *S. aureus*. Fluoroquinolones show a concentration-dependent killing effect for susceptible organisms, with higher concentrations of fluoroquinolones resulting in more complete killing [37, 38]. Thus, the hydrolytic rate of LVFX-3D<sub>6</sub> appears to be an important determinant of the maximal anti-microbial effect. NFLX-7D<sub>6</sub> did not release NFLX and did not

show any effect. These findings emphasize the importance of ensuring an appropriate susceptibility of the acidic oligopeptide-tagged drug to biological hydrolysis. To improve the effectiveness of the tagged drug, further modification is required, possibly devising a linkage susceptible to osteoclast-derived acid, peptidase, or non-specific esterase.

### **Oligopeptide-tagged enzyme for deficiency of tissue-non-specific alkaline phosphatase**

Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization and is caused by a deficiency in tissue-non-specific alkaline phosphatase (TNSALP). Despite the presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals, clinical manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization, manifesting as rickets in infants and children and osteomalacia in adults [39]. ALP functions as an inorganic pyrophosphatase in bone [40, 41]. Inorganic pyrophosphate ( $PP_i$ ) itself impairs the growth of HAP crystals and acts as an inhibitor of mineralization [42-45]. With insufficient TNSALP activity,  $PP_i$  is not adequately hydrolyzed, and the resulting build-up of unhydrolyzed  $PP_i$  in the perivesicular matrix inhibits the proliferation of pre-formed HAP crystals beyond the protective confines of matrix vesicle (MV) membranes.

Hypophosphatasia is caused by the deficiency of a single enzyme, TNSALP, making the disorder potentially amenable to enzyme replacement therapy (ERT). However, the results of ERT with intravenous infusion of plasma ALP or purified liver ALP in patients with hypophosphatasia have been disappointing [46-50]. Recently, one report has suggested that continuous delivery of

a high dose of TNSALP to bone would be needed to induce physiological bone mineralization [51]. These observations suggest that the ALP enzymes administered intravenously were mostly consumed in the visceral organs and thus were not actually delivered to the bone at the physiological levels necessary to rescue the lesions. Therefore, it was tried to develop TNSALP targeted to bone by acidic oligopeptide.

The cDNAs were designed for two enzymes: anchorless recombinant human TNSALP (rhTNSALP) and anchorless human TNSALP (about 80 kDa) tagged with a stretch of six L-Asp residues at the C terminus (CD<sub>6</sub>-TNSALP) (Fig. 6) [52]. When these cDNAs were transfected into Chinese hamster ovary (CHO-K1) cells, the enzymes were secreted from the cells into the culture medium, because they do not have the glycosylphosphatidylinositol anchoring signal peptide sequence from the C-terminus of human TNSALP cDNA. There was no significant difference in specific activity, Michaelis constant, or  $k_{cat}$  between the two enzymes. Thus, CD<sub>6</sub>-TNSALP can restore mineralization in hypophosphatasia patients. Indeed, in cultures of hypophosphatasia patient-derived bone marrow cells, the tagged enzyme markedly improved mineralization, similar to the untagged enzyme rhTNSALP. Although PP<sub>i</sub> completely inhibited the mineralization, even in the presence of P<sub>i</sub>, the addition of CD<sub>6</sub>-TNSALP restored the mineralization level to that of the PP<sub>i</sub>-free control culture, as did TNSALP. Consequently, it seems that both the tagged and untagged enzymes may be taken up without modification into osteoblastic cells, possibly by endocytosis, and that both show similar bioactivity in terms of mineralization, by degrading PP<sub>i</sub> in the cells.

To evaluate the pharmacokinetic tissue distribution of the enzymes, fluorescently labeled enzymes were prepared with the Alexa dye. CD<sub>6</sub>-TNSALP showed about a 2-4-fold increase in bone retention, compared with untagged TNSALP, for at least 7 days after intravenous injection. The distribution to other tissues was not significantly different between the two enzymes, although the half-lives in the circulation were slightly different (rhTNSALP, 19.1 h; CD<sub>6</sub>-TNSALP, 14.4 h) after a single intravenous injection. The different half-lives in the circulation may have been due to the different carbohydrate structures, i.e., the tagged enzyme was less sialylated than the untagged enzyme, based on the result of lectin affinity chromatography [52]. It is known that higher sialic acid residue content at the terminus of the carbohydrate chain contributes to a longer half-life of ALP in the blood [53, 54].

These results suggest the possible clinical application of ERT for hypophosphatasia, although further studies are needed to confirm *in vivo* and clinical effectiveness of the tagged enzyme and may encourage us to develop drugs of other large molecule such as growth factors or hormones tagged with acidic oligopeptides for some bone diseases and growth disorder.

### **Bisphosphonates and acidic oligopeptides as bone targeting carrier**

Fujisaki et al. [3,4] designed a hybrid compound of estradiol and bisphosphonate. This compound was rapidly taken up by bone and increased BMD of OVX rats. But this hybrid compound also increased the uterine weight to have intrinsic hormonal action on estrogen receptors, indicating missing in selectivity to the bone. Many investigators have tried to

selectively deliver of several biological active proteins to bone, but none has been successful so far in targeting the molecules to the bone and showing that they have the desired biological effect on the bone. Uludag et al. [5,6] have designed aminobisphosphonate conjugated with bovine serum albumin and succeeded in delivery the protein to bone with several fold higher concentration and longer retention than unconjugated protein. However, because the cleavage and release the bioactive protein from the conjugate may be difficult, it has not been proved until now to exhibit the bioactivity on bone after administration of the conjugate of bisphosphonate and some biologically active protein or peptide.

Our small peptide consisting of an acidic amino acid may be more practical as a bone-targeting carrier of various drugs for treatment of bone diseases, because it is selectively distributed to the bone, where it gradually releases the conjugated drug, whereas it is rapidly degraded and removed from plasma [10,11]. On the other hand, a genetically prepared TNSALP tagged with six L-Asp oligopeptide at the C terminus accomplished higher accumulation and longer retention in the bone than untagged enzyme [52]. Furthermore the tagged enzyme improved mineralization of bone-marrow cells from patient of hypophosphatasia, similar to the untagged enzyme [52], suggesting the carrier peptide does not influence the enzyme activity, because the molecular size is too small compared with the parent enzyme.

## **Conclusion**

The cumulative results of the studies on acidic oligopeptide conjugation indicate a promising

method of selectively delivering drugs to bone. Owing to the apparently strong affinity of acidic oligopeptides for HAP, the targeting system may be widely applicable for both small molecule drugs and large molecules as proteins in several bone diseases.

The presence of an acidic oligopeptide tag altered the drug's pharmacokinetic and biological properties, including blood clearance, distribution to visceral organs, and biological activity. The increased hydrophilicity created by the tag is thought to be responsible for these alterations. In considering clinical use, it is unlikely that tagged molecules would be suitable for oral administration because of their high hydrophilicity and their susceptibility to peptidases and esterases in the gastrointestinal tract. Other routes of administration, such as the intranasal route, may increase the bioavailability of tagged molecules, and the greater convenience may improve compliance and patient quality of life.

## References

1. De Ligny CL, Gelseman WJ, Tji TG, Huigen YM, Vink HA (1990) Bone-seeking radiopharmaceuticals. Nucl Med Biol 17: 161-179
2. Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Delivery Rev 42: 175-195
3. Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T (1995) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 3: 273-282
4. Fujisaki J, Tokunaga Y, Takahashi T, Shimojo F, Kimura S, Hata T (1998) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I.v. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J Drug Target 5: 129-138
5. Uludag H, Gao T, Wohl GR, Kantoci D, Zernicke RF (2000) Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnol Prog 16: 1115-1118
6. Gittens SA, Bansal G, Zernicke RF, Uludag H (2005) Designing proteins for bone targeting. Adv Drug Delivery Rev 57: 1011-1036
7. Oldberg A, Franzén A, Heinegård D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83: 8819-8823
8. Nagata T, Bellows CG, Kasugai S, Butler WT, Sodek J (1991) Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC

- (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. *Biochem J* 274: 513-520
9. Kasugai S, Nagata T, Sodek J (1992) Temporal studies on the tissue compartmentalization of bone sialoprotein (BSP), osteopontin (OPN), and SPARC protein during bone formation in vitro. *J Cell Physiol* 152: 467-477
  10. Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M, Sawanishi H, Morito K, Masamune Y, Kasugai S, Yokogawa K, Miyamoto K (2001) Novel drug delivery system to bone using acidic oligopeptide; pharmacokinetic characteristics and pharmacological potential. *J Drug Target* 9: 111-121
  11. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K (2000) Selective drug delivery system to bone; small peptide (Asp)<sub>6</sub> conjugation. *J Bone Miner Res* 15: 936-943
  12. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. *Science* 241: 81-84
  13. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. *Science* 241: 84-86
  14. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC (1991) Avian osteoclasts as estrogen target cells. *Proc Natl Acad Sci USA* 88: 6613-6617
  15. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T (1997) Expression of estrogen receptor beta in rat bone. *Endocrinology* 138: 4509-4512

16. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Löwik CW, Pols HA, van Leeuwen JP (1997) Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. *Endocrinology* 138: 5067-5070
17. Bain SD, Bailey MC, Edwards MW (1992) The anabolic effect of estrogen on endosteal bone formation in the mouse is attenuated by ovariectomy; a role for the uterus in the skeletal response to estrogen? *Calcif Tissue Int* 51: 223-228
18. Wronski TJ, Yen CF, Qi H, Dann LM (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. *Endocrinology* 132: 823-831
19. Lindsay R, Tohme JF (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. *Obstet Gynecol* 76: 290-295
20. Astedt B (1981) On the role of estrogens in endometrial carcinogenesis. *Acta Obstet Gynecol Scand* 106(Suppl): 33-35
21. Gambrell RD (1982) The menopause; benefits and risks of estrogen-progestogen replacement therapy. *Fertil Steril* 37: 457-474
22. Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, Morito K, Masamune Y, Waki Y, Kasugai S, Miyamoto K (2001) Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. *Endocrinology* 142: 1228-1233
23. Lerner JM, MacLusky NJ, Hochberg RB (1985) The naturally occurring C-17 fatty acid esters of estradiol are long-acting estrogens. *J Steroid Biochem* 22: 407-413

24. Larner JM, Hochberg RB (1985) The clearance and metabolism of estradiol and estradiol-17-esters in the rat. *Endocrinology* 117: 1209-1214
25. Hershcopf RJ, Bradlow HL, Fishman J, Swaneck GE, Larner JM, Hochberg RB (1985) Metabolism of estradiol fatty acid esters in man. *J Clin Endocrinol Metab* 61: 1071-1075
26. Yokogawa K, Toshima K, Yamoto K, Nishioka T, Sakura N, Miyamoto K (2006) Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol. *Biol Pharm Bull* 29: 1229-1233
27. Dirschl DR, Almekinders LC (1993) Osteomyelitis. Common causes and treatment recommendations. *Drugs* 45: 29-43
28. Mader JT, Ortiz M, Calhoun JH (1996) Update on the diagnosis and management of osteomyelitis. *Clin Podiatr Med Surg* 13: 701-724
29. Mader JT, Mohan D, Calhoun J (1997) A practical guide to the diagnosis and management of bone and joint infections. *Drugs* 54: 253-264
30. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB (1987) Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. *Am J Med* 83: 218-222
31. Mader JT, Cantrell JS, Calhoun J (1990) Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. *J Bone Joint Surg Am* 72: 104-110.
32. Takahashi TN, Kobayashi S, Miyamoto K (2008) Bone targeting of quinolone antibiotics

conjugated with an acidic oligopeptide. *Pharm Res* (In press)

33. Lewis RJ, Tsai FT, Wigley DB (1996) Molecular mechanisms of drug inhibition of DNA gyrase. *Bioessays* 18: 661-67.
34. Shen LL, Chu DTW (1996) Type II DNA topoisomerases as antibacterial targets. *Curr Pharm Des* 2: 195-208
35. Blondeau JM (1999) Expanded activity and utility of the new fluoroquinolones; a review. *Clin Ther* 21: 3-40
36. O'Donnell JA, Gelone SP (2000) Fluoroquinolones. *Infect. Dis Clin North Am* 14: 489-513
37. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. *Antimicrob Agents Chemother* 31: 1054-1060
38. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M (1998) Pharmacodynamics of levofloxacin; a new paradigm for early clinical trials. *JAMA* 279: 125-129
39. Whyte MP (2001) Hypophosphatasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) *The Metabolic and Molecular Bases of Inherited Disease*, 8th Ed. McGraw-Hill, New York, pp 5313-5329
40. Moss DW, Eaton RH, Smith JK, Whitby LG (1967) Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. *Biochem*

J 102: 53-57

41. Leone FA, Rezende LA, Ciancaglini P, Pizauro JM (1998) Allosteric modulation of pyrophosphatase activity of rat osseous plate alkaline phosphatase by magnesium ions. *Int J Biochem Cell Biol* 30: 89-97
42. Anderson HC (1988) Mechanisms of pathologic calcification. *Rheum Dis Clin North Am* 14: 303-319
43. Fleisch H, Russell RG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. *Nature* 212: 901-903
44. de Jong AS, Hak TJ, van Duijn P (1980) The dynamics of calcium phosphate precipitation studied with a new polyacrylamide steady state matrix-model; influence of pyrophosphate collagen and chondroitin sulfate. *Connect Tissue Res* 7: 73-79
45. Meyer JL (1984) Can biological calcification occur in the presence of pyrophosphate? *Arch Biochem Biophys* 231: 1-8
46. Whyte MP, Valdes R, Ryan LM, McAlister WH (1982) Infantile hypophosphatasia; enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. *J Pediatr* 101: 379-386
47. Whyte MP, McAlister WH, Patton LS, Magill HL, Fallon MD, Lorentz WB, Herrod HG (1984) Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma; results in three additional patients. *J Pediatr* 105: 926-933

48. Whyte MP, Magill HL, Fallon MD, Herrod HG (1986) Infantile hypophosphatasia; normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase. *J Pediatr* 108: 82-88
49. Weninger M, Stinson RA, Plenk H, Böck P, Pollak A (1989) Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. *Acta Paediatr Scand* 360: 154-160
50. Whyte MP, Landt M, Ryan LM, Mulivor RA, Henthorn PS, Fedde KN, Mahuren JD, Coburn SP (1995) Alkaline phosphatase; placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. *J Clin Invest* 95: 1440-1445
51. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. *Genes Dev* 19: 1093-1104
52. Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Trandafirescu GG, Lopez PL, Grubb JH, Kanai R, Kobayashi H, Yamaguchi S, Gottesman GS, Cahill R, Noguchi A, Sly WS (2006) Enhancement of drug delivery to bone; characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. *Mol Genet Metab* 88: 244-255
53. Walton RJ, Preston CJ, Russell RG, Kanis JA (1975) An estimate of the turnover rate of

bone-derived plasma alkaline phosphatase in Paget's disease. *Clin Chim Acta* 63: 227-229

54. Komoda T, Sakagishi Y (1987) The function of carbohydrate moiety and alteration of carbohydrate composition in human alkaline phosphatase isoenzymes. *Biochim Biophys Acta*, 523: 395-406

Fig. 1. Amino acid sequences of bone matrix proteins

### Bone sialoprotein

MKTALILLSILGMACAFSMKNLHRRVKI**EDSEENG**VFKYRPRYYLYKHAYFYPHLKRFPVQGS**SD**  
SS**EE**NG**DD**SS**EEEEEEEE**ETS**NE**GEN**NE**ES**NEDE**DE**SEA**ENTTL**S**ATTLGY**GED**ATPGTGYTGLAAI  
QLPKKAG**D**ITNKATK**EKESDEEEEEEE**GN**ENE**ES**EA**EVD**ENE**QGINGTSTNST**EA**ENGNGSS**GE**  
**D**NG**EE**GE**EE**SVTGANA**E**GT**TE**TGGQ**G**KGTSKTTT**SP**NGGF**E**PTTP**P**QVYRTT**SP**PF**G**KTTT**VE**YE  
**GE**YEYTGANDY**D**NGYE**I**YE**SE**NG**E**PRGDNYRAY**E**DEYSYFKGQGY**D**GY**D**GQNY**Y**HHQ

### Osteopontin

MRIAVICFCLLGITCAIPVKQAD**S**GS**SE**EKQLYNKYP**D**AVATWLNP**D**PSQKQ**N**LLAPQTLPSKSN  
**E**SHDHMD**DD**ED**DD**DDHVDSQ**D**S**I**DS**N**DS**DD**V**DD**T**DD**SHQ**S**DESHHS**DE**DELVTDFPTDL**P**ATE  
VF**T**PVVPTV**D**TY**D**GR**G**DSVVYGLRSKSKK**F**RR**P**DIQYP**D**AT**DE**DITSH**M**ES**E**ELNGAYKAI**P**VAQ  
**D**LNAP**S**D**W**DSRG**K**DSY**E**TS**Q**L**DD**Q**S**A**E**THSHKQ**S**R**L**YKR**K**AN**DE**S**NE**HS**D**V**I**DS**Q**ELSKV**S**R**E**FH  
S**E**FHS**H**ED**M**L**V**DPK**S**KE**E**DKHLK**F**R**I**SH**E**LD**S**AS**S**EV**N**

Acidic amino acids are emphasized.

Fig. 2. Structure of FITC-D<sub>6</sub>





Fig. 3. Confocal laser scanning microscopic images of bones



Ground sections of bones were prepared from rats 24 h after injection with FITC-D<sub>6</sub>.

Fig. 4. Structures of  $E_2-3D_6$  and  $E_2-17\beta D_6$





Fig. 5. Structures of NFLX-7D<sub>6</sub> and LVFX-3D<sub>6</sub>





Table 1. Pharmacokinetic parameters after an intravenous administration of fluoroquinolones and their Asp-oligopeptide tagged drugs

	LVFX (27.7 $\mu\text{mol/kg}$ )	LVFX-3D <sub>6</sub> (27.7 $\mu\text{mol/kg}$ )	NFLX (31.3 $\mu\text{mol/kg}$ )	NFLX-7D <sub>6</sub> (31.3 $\mu\text{mol/kg}$ )
AUC <sub>0-2 h</sub> (nmol/mL·h)	8.77 $\pm$ 0.39	24.8 $\pm$ 0.8*	9.66 $\pm$ 1.70	20.7 $\pm$ 7.8*
Vd <sub>ss</sub> (L/kg)	1.55 $\pm$ 0.04	0.27 $\pm$ 0.06*	1.86 $\pm$ 0.35	0.63 $\pm$ 0.14*
t <sub>1/2</sub> (h)	0.49 $\pm$ 0.09	0.38 $\pm$ 0.02	0.52 $\pm$ 0.09	0.62 $\pm$ 0.17

Each compound was injected into the jugular vein of mice at the indicated dose. Each value represents the mean  $\pm$  S.D. (n = 4).

\*Significantly different from the parent drug at  $p < 0.05$ .

Fig. 6. DNA construct of CD<sub>6</sub>-TNSALP

